Meet our expert

ilan-behm_headshot-copy

Real-World Data Expert

Ilan Behm

VP, Head of Real-World Data Analytics, Insights & Platform Services
With two decades of experience in healthcare analytics, Ilan Behm serves as a key leader driving client success at Norstella through real-world data expertise. His previous experience includes work at a life sciences consulting firm, where he used claims data to support its payer strategy. Ilan’s team at Norstella uses claims, lab and EMR data to ensure our real-world data initiatives not only meet expectations, but leave a strong, lasting impression on our clients.

What is your role at Norstella?

I lead the RWD Engagement function at Norstella, a relatively new team comprised of consultants, managers, directors, clinicians, and researchers who live and breathe Norstella RWD data daily. The team is hands-on with claims, lab and EMR data, and their role is making sure the work we deliver from a real-world data (RWD) perspective not only meets expectations, but leaves a strong, lasting impression. I want clients to walk away thinking, That was great—let’s work with Norstella again. Whether it’s renewing, expanding, or bringing us along to a new company, the goal is to make our data, and our services, indispensable.

Tell us about your real-world data expertise.

I’ve been in healthcare analytics for almost 20 years now. I kind of stumbled into pharma—about 12 or 14 years ago when I joined a small life sciences consulting firm that used claims data to support their payer strategy. That’s where I learned SQL and really got my hands dirty. I traveled a lot, talked to pharma clients, learned how to interpret the data—and never looked back.

What’s been one of the most rewarding or exciting projects that you’ve been a part of and why?

We’re still early in implementation, but some of the derived metrics the team has put together shed a new light on clinical trial performance and opportunity to get more patients involved in clinical trials, with the end goal of accelerating the time to market for Phase III assets.

What does a day in the life of a real-world data analyst look like at Norstella?

Honestly, most of the work comes down to problem-solving. Our clients are trying to solve a problem—that’s why they came to us. We work with them to understand what they’re trying to accomplish/solve for and then translate that into specifications that can be mapped on to RWD. From there we take the RWD and either deliver it so that they can use it to answer their questions, or we analyze the data to answer the questions for them. A typical day is a mix of talking with clients, analyzing data in SQL or IHD, and putting together insights in Excel and PPT.

What types of problems does real-world data help pharma solve?

Broadly, we are helping clients accelerate patient access to therapies using NorstellaLinQ RWD. On the commercial side, we’re doing that through patient identification, patient-journey mapping, HCP targeting/segmentation, and field triggers/alerts. On the medical/HEOR side, we’re partnering to quantify the clinical and economic burden of disease so that clients can best articulate the value proposition of their therapies. On the clinical side, we’re helping accelerate clinical trials through site identification and patient altering for trial sites.

When you’re not analyzing data, what do you like to do?

Tennis and travel are my go-tos. I live in Colorado, so with its amazing outdoor scene, we’re always hiking or exploring. That’s why we moved here—Boston winters are no joke! With two kids, it’s great to have space and sunshine.

Published insights

Use Case

NorstellaLinQ: Integrated data and analytic expertise for a competitive edge in the breast cancer market

In this use case, find out how MMIT, using NorstellaLinQ, used real-world data to deliver insights to support a breast cancer drug’s strategic positioning, market evolution, and long-term growth planning.
Case Study

NorstellaLinQ: Empowering early disease diagnosis with real-world data

In this case study, learn how MMIT, utilizing NorstellaLinQ, integrated unstructured EMR data with structured data to assist a global pharmaceutical company in identifying disease screening patterns and formulating effective commercialization strategies.
Webinar

Uncovering new rare disease patients using structured and unstructured real-world data

Rare disease patient populations are often difficult to identify due to limited prevalence and fragmented data sources. In this webinar, MMIT experts show how NorstellaLinQ integrates structured and unstructured real-world data—including EMR, claims, and lab results—to quantify rare disease populations, develop commercial and payer targeting strategies, and create robust HEOR stories to support market access and evidence generation.
Article

How unstructured EMR data helps pharma find patients

As therapies have become more complex, pharma companies are now challenged to achieve precision targeting within a much tighter timeframe. While claims data is readily available, one of its key limitations is the lack of timeliness.
Article

Mining the hidden gems in unstructured EMR data

Pharma companies are increasingly turning to real-world data to answer their commercial business questions, but not all realize that unstructured EMR data is the unsung hero of most queries. Whether a manufacturer is struggling to find a niche patient population, conduct unbiased outcomes research, or generate persuasive proof points, unstructured data can fill in the gaps left by other real-world data sources.
Article

How integrated real-world data helps identify and improve outcomes for rare disease patients

Rare diseases pose a significant challenge for healthcare systems, patients and pharmaceutical companies alike. The journey from symptom onset to diagnosis and treatment can take years—sometimes even decades. The scattered and often incomplete data associated with these conditions makes it difficult to identify patients early, track disease progression and improve outcomes.

Our AI capabilities are built to evolve—transforming data into insight, insight into action, and action into impact.